US EditionEli Lilly's Oral GLP-1 Pill Achieves Key Milestones in Diabetes and Weight Loss Treatment
- Eli Lilly announced its oral obesity pill, Orforglipron, met the company's goals in trials for Type 2 diabetes treatment, helping patients lower blood sugar and body weight safely, comparable to injections available.
- The highest dose of the pill resulted in an average weight loss of 16 pounds, with a reduction in A1C levels between 1.3% and 1.6% after 40 weeks, demonstrating safety comparable to current injectable options.
- Eli Lilly plans to seek regulatory approval for Orforglipron as an obesity treatment by the end of 2025, with diabetes approval expected in 2026, and is ahead of competitors in this market.
- The pill's results received praise from industry experts, noting the advantages of a pill over injections for patient accessibility.
94 Articles
94 Articles
What is the weight-loss drug Orfoglipron and could it replace Ozempic?
The once dailly pill is still going through trials (Picture: Getty) Ozempic has skyrocketed in popularity within the past two years, causing Weight Watchers to file for bankruptcy. But the popular injection is seeing new competition with Mounjaro, and now a daily pill which could help patients lose 16 pounds in just nine months. The pill Orforglipron is used to treat Type 2 diabetes and obesity, and trials have shown participants had lower blood…
Watauga Democrat
knoxvilledailysun.comFirst Weight-Loss Pill From Lilly Shows Promising Results
Key Takeaways
Novo Nordisk Is Getting Absolutely Destroyed
Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight loss drugs Ozempic and Wegovy, have been absolutely plummeting. The company's stock price slid over eight percent on Thursday, after its main competitor in the space, US-based pharmaceutical company Eli Lilly, announced promising Phase 3 trial results for its GLP-1 pill orforglipron, which is being marketed under its brand name CagriSema. According t…
Who could take new weight-loss pill - and who should avoid it
The first daily weight-loss pill is expected to be available in the UK as soon as next year after a trial found it to be effective in treating obesity and diabetes.The drug, developed by Eli Lilly and called orforglipron, targets the same GLP-1 receptors as Ozempic, Wegovy and Mounjaro.If the drug gets approved by regulators, it would be a more convenient option that is expected to reach blockbuster status.Here, The i Paper takes a look at what …
Eli Lilly Skyrockets After Promising Results for First Weight-Loss Pill
After the tireless, incredible work by the scientists involved, the marketing team will barely have to lift a finger to come up with something catchier than orforglipron, as the company’s potentially game-changing drug has been dubbed. Eli Lilly announced trial results Thursday that suggested the experimental pill for diabetes and weight loss is just as effective as rival Novo Nordisk’s blockbuster injectable diet drug Ozempic. The company plans…
Coverage Details
Bias Distribution
- 55% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
